Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SYMBA SEC Admin proceeding for delinquent Financials:
http://www.sec.gov/litigation/admin/2014/34-72341.pdf
What is going on with this company?
hi clci ...nite moved to .30
:)
SYMBA @ .013!
How can you have Volume: 299,450 to the positive and no movement in price?
SYMBA - New PR:
http://finance.yahoo.com/news/Clear-Channel-Communications-pz-4291098067.html?x=0&.v=1
Clear Channel Communications Partners With Symbollon Pharmacueticals, Hi-Health and Mayo Clinic Scottsdale to Support Breast Cancer Research in the "Shop 4 the Cause"
MEDFIELD, Mass., Oct. 12, 2010 (GLOBE NEWSWIRE) -- Symbollon Pharmaceuticals, Inc. (OTCBB:SYMBA - News) (www.symbollon.com) in honor of National Breast Cancer Awareness Month, beginning October 1, 2010 Phoenix area radio station, KEZ, and one of its sponsors, the Scottsdale Medical Imaging, have created "Shopping 4 the Cause". Throughout the month of October, KEZ listeners are invited to shop at our partnering businesses where a portion of their shopping will go directly to breast cancer research at the Mayo Clinic. Other participating partner companies in the Shop 4 the Cause program are: Safeway, Hi-Health, Liberty Buick, Liberty GMC and Peoria Kia.
Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals, Inc. stated that, "We are thrilled to be participating in the Shop 4 the Cause program. We have entered into an exclusive vendor agreement with the Hi-Health stores to sell Iogen(TM) in the Arizona retail markets. During the month of October, Symbollon will donate a part of its proceeds to breast cancer research as part of the Shop 4 the Cause Program." He went on to say that "Hi-Health Stores sell the highest quality health foods, nutritional supplements and provide extensive education to their customers throughout their 47 retail stores chain in Arizona. Hi-Health's staff constantly strive to ensure that the health and nutrition information they provide is based on respected scientific studies. Iogen(TM) is the first dietary supplement formulated to promote breast health for women. Iogen(TM) has been clinically tested in over 2,000 women with fibrocystic breast disease, including breast pain and tenderness and benign breast lumps and cysts."
Clear Channel/Phoenix President and Market Manager Jeff England said, "It is most gratifying when we are able to bring listeners, clients, and KEZ together for a great cause."
Sean Johnson, General Sales Manager for KEZ had this to say, "We know our listeners love to shop, and we want to give them a way to take part in this important cause, while doing the things they love to do anyways in their daily lives. Shopping...and helping to fight breast cancer...what could be more KEZ?" Log on to KEZ999.com, keyword; Shopping, for details on what each partner is contributing to Shopping 4 the Cause.
Jay Chopra V.P. Merchandising for Hi-Health Stores said, "Iogen(TM) is the first of its kind, formulated to promote breast health for women and proven clinically safe product with impressive efficacy. Hi-Health is excited to be the first to carry the product to Arizona retail supplement market."
Through the company efforts, Iogen(TM) is already available in the following Hi-Health locations: http://hihealth.com/about/locations.html
About Hi-Health Stores Since 1972, with 47 retail stores Hi-Health has been helping people improve their health through better nutrition. We offer our customers the highest quality health foods and nutritional supplements. Our well trained and experienced staff is dedicated to providing customers the best product information and customer service available from a health food store. Hi-Health has been under the same ownership, direction and leadership for over thirty-eight years. Our persistent commitment to quality and customer service has made us a recognized leader in the health food industry. The country's most respected shopping center developers have actively sought to include our stylish and innovative stores in their properties. For more information on Hi-Health and the products visit their website at www.hihealth.com.
About Clear Channel Communications, Inc. (OTCBB:CCMO - News), Clear Channel Radio Phoenix
Clear Channel Radio Phoenix comprises KNIX-FM 102.5, KESZ-FM 99.9, KYOT-FM 95.5, KMXP-FM 96.9, KZZP-FM,104.7, KFYI-AM 550, KGME-AM 910 and KOY-AM 1230. Clear Channel Radio Phoenix is part of Clear Channel Radio, a leading radio company focused on serving local communities across the U.S. with more than 110 million listeners choosing Clear Channel Radio programming each week. The company's content can be heard on AM/FM stations, HD digital radio channels, on the Internet, via iPods and cell phones and used via navigation systems from BMW, Volvo, TomTom, Garmin and others. The company's operations include radio broadcasting, syndication and independent media representation. Clear Channel Radio is a division of Clear Channel Communications, Inc. (OTCBB:CCMO - News), a leading global media and entertainment company. More information on the company can be found at www.clearchannel.com.
About Symbollon Pharmaceuticals, Inc. (OTCBB:SYMBA - News)
Symbollon is a specialty life science company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. Iogen is a dietary supplement formulated for women suffering from the symptoms of fibrocystic breast disease, including breast pain and tenderness and benign breast lumps and cysts. For more information about Symbollon and IOGEN, please visit the company's website at http://www.symbollon.com.
The Symbollon Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7640
Forward Looking Statement This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize Iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.
Contact:
Premier Media Service Inc.
Kelly Black, President
866-216-8814
480-649-8224
kblack@premiermediaservice.com
yeah
totally confusing and still should come with a warning but...
with a recent contract signed and internal acquisitions I wonder whats up with the going concern status
confused
yeah
totally confusing and still should come with a warning but...
with a recent contract signed and internal acquisitions I wonder whats up with the going concern status
confused
Not sure the jump in SP is right based on what we know, I will watch
still highly spec as well, not a great track record
no real recent financial numbers is one reason this is dead
Awesome News, wish I had money in the bank ;)
any other comments on the company?
that link is dead
SYMBA PR hit the wire today:
http://finance.yahoo.com/news/Symbollon-Forms-Joint-Venture-pz-2545414637.html?x=0&.v=1
.22 volume has slowed hopefully it picks up soon
Added to The Stock Wizards Hot stocks list today
MEDFIELD, MA, Mar 04, 2010 Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) is pleased to announce that it has initiated retail sales of iogen(TM), its patented dietary supplement for improving women’s breast health, through its web site, www.buyiogen.com. Iogen is the first dietary supplement formulated to promote breast health for women. As part of the initial launch, iogen will be available for a limited-time introductory price of $19.95 (a 70% discount off the retail price) for a 2-month supply. The offer is backed by a 60-day money back guarantee.
Technical outlook: SYMBA broke a critical resistance level of .20 in this morning’s trading. A weekly close above this level would be very bullish for the stock. The technicals are very strong on the charts. SYMBA is up 65% on 671 million shares in early trading.
About Symbollon Pharmaceuticals, Inc. (OTCBB: Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) ) Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women’s healthcare and antimicrobials uses. For more information about Symbollon, please visit the company’s website at http://www.symbollon.com.
SYMBA to Dollar Land, time to accumulate!!!
Gumzaaaaaaaaaaaaaaaaaaa, great to see you here Amigo!!!
SYMBA .26 got some at open. lets goooooooooooooooo
SYMBA to DOLLA$$$$$$!!!!!
Great news, Thanks Trend Trader!!!!
This is amazing!
SYMBA NEWS!
Symbollon Hits Its First Major Milestone
Symbollon Initiates Sales of iogen Through Web Site buyiogen.com
MEDFIELD, MA, Mar 04, 2010 (MARKETWIRE via COMTEX) -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) is pleased to announce that it has initiated retail sales of iogen(TM), its patented dietary supplement for improving women's breast health, through its web site, www.buyiogen.com. Iogen is the first dietary supplement formulated to promote breast health for women. As part of the initial launch, iogen will be available for a limited-time introductory price of $19.95 (a 70% discount off the retail price) for a 2-month supply. The offer is backed by a 60-day money back guarantee.
"Our company has hit its first significant milestone," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We are pleased to make iogen available now to women through our newly designed web site, www.buyiogen.com. Iogen is the first dietary supplement clinically shown to promote breast health. We believe that iogen addresses a significant need for women concerned about improving their breast health. The introductory offer will allow women to try iogen for 2 months without any financial risk. We are so confident that women suffering from breast pain or fibrocystic breast disease will be completely satisfied with the product that we are backing our introductory offer with a no questions money back guarantee. With our most recent announcement of our commercialization advisory board and the talent that has joined Symbollon, we are diligently pursuing additional retail distribution channels for our product. We are committed to making iogen available in as many outlets as possible so every woman who has interest in improving her breast health has easy access to it."
Symbollon Pharmaceuticals, Inc. Resources:
-- Corporate Profile: http://symbollon.com/corporate_profile.htm
-- FAQ: http://symbollon.com/faq.htm
-- Technology Overview: http://symbollon.com/technology_overview.htm
About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) Symbollon is a specialty biotechnology company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Forward-Looking Statement This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) we will be able to complete the acquisition of New Zealand Pure under the terms of the letter of intent, (v) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.
Contact:
Alex Johnston
Investor Relations
480-315-9982
Premier Media Service Inc.
Kelly Black
President
866-216-8814
SYMBA huge huge launch today of IoGen which is a Iodine pill. Known to also kill cancer cells. Can you imagine if you have cancer and you buy Iogen and are free of cancer in a few months. Huge huge lauch that happens today for SYMBA. new website is up also. This will be huge since SYMBA has a Low float and Low OS for a pharma blockbuster stock. Lets hope this stock does what VRML.pk has done after fda approval from .01 to $32+ in a few months.
http://jeffreydachmd114.vox.com/library/post/dr-dach-on-iodine.html?_c=feed-atom
http://www.buyiogen.com/
iogen may be the answer for your breast health†...
Backed by clinical research to positively impact female reproductive tissue.
The first and only product that delivers 100% molecular iodine.
Formulated with selenium and magnesium for maximum effectiveness.
Clinically proven to be the least thyrotoxic iodine-based product on the market
The benefits of using iogen.
The patented iogen formulation is the only product that delivers pure 100% molecular iodine. The tablet contains two inert ingredients with a basis pH. Once ingested, the tablet travels to your stomach where it starts to dissolve. There the tablet’s inert ingredients react with the acids in your stomach to create molecular iodine (I2).
Symba officially launches IoGen today a BILLION $ drug for Breast Disease/Cancer. Iodine is know to killl cancer cells of the breast and lungs per the trisla that Symbollon had with the FDA. This will be huge since SYMBA has a Low float and Low OS for a pharma blockbuster stock. Lets hope this stock does what VRML.pk has done after fda approval from .01 to $32+ in a few months.
http://www.buyiogen.com/
iogen may be the answer for your breast health†...
Backed by clinical research to positively impact female reproductive tissue.
The first and only product that delivers 100% molecular iodine.
Formulated with selenium and magnesium for maximum effectiveness.
Clinically proven to be the least thyrotoxic iodine-based product on the market
The benefits of using iogen.
The patented iogen formulation is the only product that delivers pure 100% molecular iodine. The tablet contains two inert ingredients with a basis pH. Once ingested, the tablet travels to your stomach where it starts to dissolve. There the tablet’s inert ingredients react with the acids in your stomach to create molecular iodine (I2).
SYMBA, WHAT A RIDE FROM .005-.20!!! Congrats All!!!!
This is great news....and Can't wait for more!
SYMBA GREAT NEWS!
Thanks Queen!!!
GLTU!!
Take a look at today's PR
SYMBA @ .095
Bid: .093 Ask:.13
Today's PR
http://finance.yahoo.com/news/Womans-Breast-Health-iw-3149514649.html?x=0&.v=1
SYMBA News Today
Symbollon Retains Atech Solutions to Enhance Web Presence and Build Retail Site for the Sales of IoGen
http://finance.yahoo.com/news/Symbollon-Retains-Atech-bw-2390230871.html?x=0&.v=1
Women’s Breast Health Supplement to Be Launched by Symbollon
http://www.businesswire.com/news/home/20100112005595/en/Women%E2%80%99s-Breast-Health-Supplement-Launched-Symbollon
Happy $$$$ Year to you too Luto!! SYMBA, what a great month, this year should be exciting!
GLTU!
Happy New Year
looks like to me we will closed the old open gap down in the next
days
is there something cooking? good buys
sign me up
huge insiders buys and no PR's?
what is brewing here?
a new NDA?
SYMBA @ .085!
What a fun day! I hope we see the same level of excitement tomorrow!
Not a bad day today:
$ 0.07 0.0415 (+145.61%) Volume: 660.86 k
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
108
|
Created
|
02/20/08
|
Type
|
Free
|
Moderators |
Symbollon Pharmaceuticals, Inc.
37 Loring Drive
Framingham, MA 01702
Outstanding Shares
16,473,340 as of Aug 13, 2008
Massive Insider activity
http://www.nasdaq.com/asp/quotes_sec.asp?mode=&kind=&timeframe=&intraday=&charttype=&splits=&earnings=&movingaverage=&lowerstudy=&comparison=&index=&symbol=SYMBA&symbol=PP&symbol=DNDN&symbol=PRAN&symbol=ALSE&symbol=EPCT&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&mkttype=&pathname=&page=filings&selected=SYMBA
http://finance.yahoo.com/q/it?s=SYMBA.OB
Results of Pivotal Study to Be Published in March 2008
Symbollon Pharmaceuticals Completes Phase III Pivotal Trial for IoGen
Thursday February 7, 12:28 pm ET
FRAMINGHAM, MA--(MARKET WIRE)--Feb 7, 2008 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) today announced the completion of its IoGen(TM) Phase III pivotal trial. The study, conducted by physicians throughout the U.S., is designed to evaluate the effectiveness of IoGen, a treatment which may be the first FDA-approved, non-hormonal therapy for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
ADVERTISEMENT
With the last of the 140 patients randomized in the trial having completed the dosing stage of the study, Symbollon is focused on closing the database. The Company anticipates that the database will be locked in March 2008 and plans to release the trial results at that time.
"We believe that the release of the Phase III data will be the most significant milestone in Symbollon's history," said Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals. "Prior to this study, we had collected clinical data on approximately 3,000 women with FBD. The current Phase III study will help determine whether IoGen can be commercialized as the first non-hormonal drug approved to treat women suffering from FBD."
Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe periodic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). FBD is a condition that affects approximately 20 to 33 million women in the U.S., and there are approximately 7 to 13 million women suffering from clinical periodic mastalgia. The Company believes IoGen also may be useful in treating and/or preventing endometriosis, ovarian cysts, and premenopausal breast cancer. Symbollon is also in preclinical development of antimicrobial products based on the same molecular iodine technology, and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.
Symbollon Pharmaceuticals, Inc. (OTC BB: SYMBA) is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its molecular iodine technology. Symbollon is conducting a Phase III clinical trial evaluating IoGen (I2) for pain/tenderness associated with fibrocystic breast disease (FBD) and/or with potential to treat cancer. Enrollment for the study closes at the end of June 2007 and results are expected to be published in Q1 2008.
The Company believes IoGen has the ability to eliminate excess cell growth in female reproductive tissue, including the breast, ovaries and uterus. Other indications for IoGen include the treatment and/or preventing endometriosis, ovarian cysts, and pre-menopausal breast cancer. The company has 25 patents in the US, with foreign counterparts, covering the technology.
While there are several breast cancer drugs on the m arket, all available hormonal therapies have significant adverse effects. In contrast, IoGen is a non-hormonal treatment that allows for safe long-term use with little or no sides effects. In fact, in the last Phase II study of IoGen there were no drug-related adverse events reported.
“We believe that the current research provides substantive support for the initiation of human clinical studies on the use of molecular iodine as a treatment for breast cancer,” stated Paul Desjourdy, President and CEO of Symbollon Pharmaceuticals, Inc. “The possibility that IoGen may be used as a treatment for breast cancer makes it all the more important that Symbollon expedite the commercialization time line for IoGen.”
Recent Developments
Symbollon announced that it would seek regulatory guidance in commercialization of IoGen in Europe. The company targeted The United Kingdom, Germany and Sweden. Symbollon has met with representatives of these regulatory bodies and has received guidance and comments, which should accelerate the commercialization of IoGen in Europe. The Company has also met with Canadian regulators and has received consistent comments that will allow for a regulatory filing after completion of the planned clinical trials.
In addition, Symbollon Pharmaceuticals announced that it is closing the enrollment of its IoGen Phase III pivotal pain study in June 2007 and anticipates announcing the study results in first quarter of 2008. The ongoing IoGen study has over 25 active sites across the United States. The study has been registered with FDA under the Protocol Registration System at ClinicalTrials.gov.
About IoGen
Symbollon has initiated a pivotal Phase III clinical trial evaluating IoGen as a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).
FBD is characterized by benign excess cell growth (fibrosis) and mastalgia. Benign fibrosis is a chronic condition that affects approximately 20 million to 33 million women in the U.S. In addition, there are approximately 7 million to 13 million women suffering from clinical cyclic mastalgia.
Product Focus
Symbollon’s free molecular iodine technology has potential uses in a number of application areas, which can be broadly grouped into two areas: women’s healthcare (as mentioned above) and antimicrobial applications.
Symbollon is in preclinical development of antimicrobial and intends to investigate the potential effectiveness of its technology in applications such as dermatology, oral care, upper respiratory tract conditions, urinary tract infection and wound care.
Symbollon has commercialized one animal drug, a bovine teat sanitizer, for use on the dairy farms to disinfect cow’s udders. The product is a powdered concentrate that delivers high levels of molecular iodine for fast and effective elimination of all pathogens.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |